Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

from PortlandTribune.com 9 months ago

Patients with low HER2 status in metastatic breast cancer can benefit from HER2-targeted treatment, potentially improving their outcomes significantly.
PortlandTribune.comhttps://www.portlandtribune.com/online_features/business_and_careers/roche-obtains-ce-mark-for-first-companion-diagnostic-to-identify-patients-with-her2-low-metastatic/article_e2b84f68-6ac6-5793-82f9-cb7d89837d38.html

The VENTANA HER2 (4B5) test, also known as PATHWAY in the US, is the sole approved companion diagnostic for assessing HER2-low status in metastatic breast cancer patients.
PortlandTribune.comhttps://www.portlandtribune.com/online_features/business_and_careers/roche-obtains-ce-mark-for-first-companion-diagnostic-to-identify-patients-with-her2-low-metastatic/article_e2b84f68-6ac6-5793-82f9-cb7d89837d38.html

Read at PortlandTribune.com

#metastatic-breast-cancer #her2-low-status #her2-targeted-treatment #companion-diagnostic #ce-mark-approval

Collection

[

...

]

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTURoche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU Briefly

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Briefly